In Europeans, who are more prone to obesity induced diabetes, blocking of GIP action on adipocytes may be more beneficial whereas it has been suggested that in Asians, GIP agonists may have a beneficial effect due to greater incidences of diabetes with impaired insulin secretion [24]. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.